Home > Research > Publications & Outputs > A novel measure of drug benefit–risk assessment...

Links

Text available via DOI:

View graph of relations

A novel measure of drug benefit–risk assessment based on Scale Loss Score

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

A novel measure of drug benefit–risk assessment based on Scale Loss Score. / Saint-Hilary, Gaelle; Robert, Veronique; Gasparini, Mauro; Jaki, Thomas Friedrich; Mozgunov, Pavel.

In: Statistical Methods in Medical Research, Vol. 28, No. 9, 01.09.2019, p. 2738-2753.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Saint-Hilary, G, Robert, V, Gasparini, M, Jaki, TF & Mozgunov, P 2019, 'A novel measure of drug benefit–risk assessment based on Scale Loss Score', Statistical Methods in Medical Research, vol. 28, no. 9, pp. 2738-2753. https://doi.org/10.1177/0962280218786526

APA

Saint-Hilary, G., Robert, V., Gasparini, M., Jaki, T. F., & Mozgunov, P. (2019). A novel measure of drug benefit–risk assessment based on Scale Loss Score. Statistical Methods in Medical Research, 28(9), 2738-2753. https://doi.org/10.1177/0962280218786526

Vancouver

Saint-Hilary G, Robert V, Gasparini M, Jaki TF, Mozgunov P. A novel measure of drug benefit–risk assessment based on Scale Loss Score. Statistical Methods in Medical Research. 2019 Sep 1;28(9):2738-2753. https://doi.org/10.1177/0962280218786526

Author

Saint-Hilary, Gaelle ; Robert, Veronique ; Gasparini, Mauro ; Jaki, Thomas Friedrich ; Mozgunov, Pavel. / A novel measure of drug benefit–risk assessment based on Scale Loss Score. In: Statistical Methods in Medical Research. 2019 ; Vol. 28, No. 9. pp. 2738-2753.

Bibtex

@article{f3a220fcf68e493fb3c04c8abd8fa290,
title = "A novel measure of drug benefit–risk assessment based on Scale Loss Score",
abstract = "Quantitative methods have been proposed to assess and compare the benefit-risk balance of treatments. Among them, multicriteria decision analysis (MCDA) is a popular decision tool as it permits to summarise the benefits and the risks of a drug in a single utility score, accounting for the preferences of the decision-makers. However, the utility score is often derived using a linear model which might lead to counter-intuitive conclusions; for example, drugs with no benefit or extreme risk could be recommended. Moreover, it assumes that the relative importance of benefits against risks is constant for all levels of benefit or risk, which might not hold for all drugs. We propose Scale Loss Score (SLoS) as a new tool for the benefit–risk assessment, which offers the same advantages as the linear multicriteria decision analysis utility score but has, in addition, desirable properties permitting to avoid recommendations of non-effective or extremely unsafe treatments, and to tolerate larger increases in risk for a given increase in benefit when the amount of benefit is small than when it is high. We present an application to a real case study on telithromycin in Community Acquired Pneumonia and Acute Bacterial Sinusitis, and we investigated the patterns of behaviour of Scale Loss Score, as compared to the linear multicriteria decision analysis, in a comprehensive simulation study.",
keywords = "Benefit–risk, bounds penalisation, decision-making, loss score, multicriteria decision analysis",
author = "Gaelle Saint-Hilary and Veronique Robert and Mauro Gasparini and Jaki, {Thomas Friedrich} and Pavel Mozgunov",
year = "2019",
month = sep,
day = "1",
doi = "10.1177/0962280218786526",
language = "English",
volume = "28",
pages = "2738--2753",
journal = "Statistical Methods in Medical Research",
issn = "0962-2802",
publisher = "SAGE Publications Ltd",
number = "9",

}

RIS

TY - JOUR

T1 - A novel measure of drug benefit–risk assessment based on Scale Loss Score

AU - Saint-Hilary, Gaelle

AU - Robert, Veronique

AU - Gasparini, Mauro

AU - Jaki, Thomas Friedrich

AU - Mozgunov, Pavel

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Quantitative methods have been proposed to assess and compare the benefit-risk balance of treatments. Among them, multicriteria decision analysis (MCDA) is a popular decision tool as it permits to summarise the benefits and the risks of a drug in a single utility score, accounting for the preferences of the decision-makers. However, the utility score is often derived using a linear model which might lead to counter-intuitive conclusions; for example, drugs with no benefit or extreme risk could be recommended. Moreover, it assumes that the relative importance of benefits against risks is constant for all levels of benefit or risk, which might not hold for all drugs. We propose Scale Loss Score (SLoS) as a new tool for the benefit–risk assessment, which offers the same advantages as the linear multicriteria decision analysis utility score but has, in addition, desirable properties permitting to avoid recommendations of non-effective or extremely unsafe treatments, and to tolerate larger increases in risk for a given increase in benefit when the amount of benefit is small than when it is high. We present an application to a real case study on telithromycin in Community Acquired Pneumonia and Acute Bacterial Sinusitis, and we investigated the patterns of behaviour of Scale Loss Score, as compared to the linear multicriteria decision analysis, in a comprehensive simulation study.

AB - Quantitative methods have been proposed to assess and compare the benefit-risk balance of treatments. Among them, multicriteria decision analysis (MCDA) is a popular decision tool as it permits to summarise the benefits and the risks of a drug in a single utility score, accounting for the preferences of the decision-makers. However, the utility score is often derived using a linear model which might lead to counter-intuitive conclusions; for example, drugs with no benefit or extreme risk could be recommended. Moreover, it assumes that the relative importance of benefits against risks is constant for all levels of benefit or risk, which might not hold for all drugs. We propose Scale Loss Score (SLoS) as a new tool for the benefit–risk assessment, which offers the same advantages as the linear multicriteria decision analysis utility score but has, in addition, desirable properties permitting to avoid recommendations of non-effective or extremely unsafe treatments, and to tolerate larger increases in risk for a given increase in benefit when the amount of benefit is small than when it is high. We present an application to a real case study on telithromycin in Community Acquired Pneumonia and Acute Bacterial Sinusitis, and we investigated the patterns of behaviour of Scale Loss Score, as compared to the linear multicriteria decision analysis, in a comprehensive simulation study.

KW - Benefit–risk

KW - bounds penalisation

KW - decision-making

KW - loss score

KW - multicriteria decision analysis

U2 - 10.1177/0962280218786526

DO - 10.1177/0962280218786526

M3 - Journal article

VL - 28

SP - 2738

EP - 2753

JO - Statistical Methods in Medical Research

JF - Statistical Methods in Medical Research

SN - 0962-2802

IS - 9

ER -